Novavax’s deal with Sanofi also allows the latter to combine its own influenza vaccines with Nuvaxovid. Sanofi is currently testing multiple COVID-19/flu combination vaccine candidates under ...

Novavax's combo and standalone flu shots triggered a 2.4–5.7x rise in immune response over baseline in seniors. Over 98% of adverse events were mild or moderate in Novavax's Phase 3 trial of ...

Shares of Moderna MRNA declined nearly 8% yesterday after it announced that it had voluntarily withdrawn a regulatory filing seeking the FDA’s approval for mRNA-1083, its investigational mRNA ...

Moderna has pulled the filing for FDA approval of its flu/COVID combination vaccine. The biotech plans to resubmit later this year with the phase 3 flu vaccine efficacy data the agency wants to see.

The FDA granted the company full approval for its vaccine for use only in adults 65 and older and those 12 to 64 who are at an increased risk from COVID-19. Skip Navigation Share on Facebook ...

Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine. The shot, Nuvaxovid, is designed for older adults and those between the ages of 12 and 64 who ...

WASHINGTON (AP) — The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with unusual restrictions. Novavax makes the nation’s only traditional ...

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad population the company had originally sought. The FDA has approved Novavax’s ...

The FDA has approved Novavax’s protein-based COVID-19 vaccine, giving some Americans another option besides messenger RNA vaccines to prevent SARS-CoV-2 infection.. The approval came with ...

The Food and Drug Administration (FDA) has approved Nuvaxovid ™ (COVID-19 Vaccine, Adjuvanted) for active immunization to prevent COVID-19 caused by SARS-Cov-2 in adults 65 years and older and ...